Cecilie H. Blimark

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group.

Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group.

Journal: British journal of haematology

Published: March 19, 2025

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.

Journal: Haematologica

Published: January 31, 2025

Income and education affect prognosis and treatment in symptomatic myeloma : A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry.

Income and education affect prognosis and treatment in symptomatic myeloma : A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry.

Journal: Annals of hematology

Published: November 21, 2024

Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.

Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.

Journal: Haematologica

Published: April 12, 2024

Respiratory syncytial virus and other vaccine-preventable infections in multiple myeloma. A population-based study on 8,672 myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.

Respiratory syncytial virus and other vaccine-preventable infections in multiple myeloma. A population-based study on 8,672 myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.

Journal: Haematologica

Published: January 26, 2024

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Journal: HemaSphere

Published: May 11, 2023

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients.

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients.

Journal: Haematologica

Published: June 20, 2022

Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden.

Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden.

Journal: Haematologica

Published: January 10, 2022

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.

Journal: Cancer reports (Hoboken, N.J.)

Published: August 01, 2021

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.

Journal: European journal of haematology

Published: June 12, 2021

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.

Journal: European journal of haematology

Published: April 02, 2021

Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.

Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.

Journal: European journal of haematology

Published: September 02, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026